Abemaciclib - Eli Lilly

Drug Profile

Abemaciclib - Eli Lilly

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY-2835219; Verzenio

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; Emory University; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Non-small cell lung cancer
  • Phase II Brain cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Pancreatic cancer
  • Phase I Cancer
  • Preclinical Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Late-stage disease) in Japan (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease) in Spain (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top